Relmada Therapeutics (NASDAQ:RLMD) Price Target Raised to $19.00

Relmada Therapeutics (NASDAQ:RLMD) had its price target increased by Mizuho from $10.00 to $19.00 in a report released on Friday morning,Benzinga reports. They currently have an outperform rating on the stock.

RLMD has been the subject of a number of other research reports. Leerink Partners upgraded Relmada Therapeutics from a “market perform” rating to an “outperform” rating and set a $8.00 price objective for the company in a research report on Friday, January 23rd. Lucid Cap Mkts upgraded Relmada Therapeutics to a “strong-buy” rating in a report on Monday, March 2nd. Zacks Research raised Relmada Therapeutics to a “hold” rating in a research report on Tuesday, January 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Relmada Therapeutics in a report on Wednesday, January 28th. Finally, Jefferies Financial Group assumed coverage on Relmada Therapeutics in a research report on Monday, December 22nd. They issued a “buy” rating and a $9.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $12.00.

Relmada Therapeutics Price Performance

NASDAQ RLMD opened at $6.07 on Friday. Relmada Therapeutics has a 12 month low of $0.24 and a 12 month high of $7.51. The company has a market capitalization of $445.11 million, a P/E ratio of -4.19 and a beta of 0.72. The company’s 50 day simple moving average is $4.50 and its 200 day simple moving average is $3.59.

Relmada Therapeutics (NASDAQ:RLMD) last issued its earnings results on Thursday, March 19th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.13). On average, analysts anticipate that Relmada Therapeutics will post -2.73 earnings per share for the current year.

Hedge Funds Weigh In On Relmada Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC acquired a new stake in Relmada Therapeutics during the 4th quarter valued at $35,041,000. Squadron Capital Management LLC acquired a new stake in shares of Relmada Therapeutics in the fourth quarter worth $32,361,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Relmada Therapeutics in the fourth quarter worth $20,624,000. Spruce Street Capital LP purchased a new position in shares of Relmada Therapeutics during the fourth quarter valued at $19,736,000. Finally, Marshall Wace LLP raised its position in Relmada Therapeutics by 1,072.4% during the fourth quarter. Marshall Wace LLP now owns 3,189,662 shares of the company’s stock valued at $15,406,000 after buying an additional 2,917,609 shares during the period. 45.24% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Relmada Therapeutics

Here are the key news stories impacting Relmada Therapeutics this week:

• Positive Sentiment: Mizuho raised its price target sharply to $19 and upgraded RLMD to “Outperform,” implying large upside from current levels — this is a clear buy-side catalyst that can drive buying interest and re-rate sentiment. Read More.
• Positive Sentiment: Company press release highlights audited Q4 and full‑year 2025 results and a corporate update describing “significant progress across its pipeline” (ongoing clinical and strategic milestones). Pipeline advancement tends to support longer-term valuation for clinical-stage biotech. Read More.
• Neutral Sentiment: Earnings call transcripts and highlights from multiple outlets provide management commentary on strategy, program timelines and cash runway; useful for investors parsing catalysts but not an immediate market mover on their own. Review the call transcript for details on enrollment, milestones and guidance. Read More.
• Negative Sentiment: Relmada reported Q4 EPS of ($0.27), missing consensus (~($0.14)) by ~$0.13 — a near-term negative that highlights continued operating losses and may pressure sentiment until clearer revenue or milestone offsets emerge. Read More.

About Relmada Therapeutics

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.